7 minute read
Dec. 26, 2023

Moving Targets: Key Clinical Readouts with TYK2, MEK1/2, PPAR Modulators and More from Nov. '23

Drug Hunter Team

An aldosterone synthase inhibitor, a pFOX inhibitor, a brain-penetrant MEK1/2 inhibitor, and several other modulators had major trial results disclosed recently. In case you missed them, this article rounds up key results of general industry interest from Nov. 23, with representative patent structures for undisclosed molecules. Read this review to get a sneak peek at potential future approvals and some informative disappointments.



Other articles you may be interested in